Evidence map›Paper›PMID 38725830›Full record

ArticleFrontiers in cardiovascular medicine2024

Divergent cardiac and renal effects of miR-181c-5p inhibition in a rodent heart failure model.

Jente R A Boen, Andreas B Gevaert, Amélie Dendooven, Dustin Krüger, Michiel Tubeeckx, Jens Van Fraeyenhove, Tine Bruyns, Vincent F M Segers, Emeline M Van Craenenbroeck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The pathophysiological role of MiRNAs in heart failure.Frontiers in cardiovascular medicine · 2026
    Review
  2. RNA Therapeutics in Heart Failure.Journal of cardiovascular translational research · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jente R A BoenResearch Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Wilrijk, Belgium.
Andreas B GevaertResearch Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Wilrijk, Belgium.
Amélie DendoovenDepartment of Pathology, Ghent University Hospital, Gent, Belgium.
Dustin KrügerLaboratory of Physiopharmacology, GENCOR Department, University of Antwerp, Wilrijk, Belgium.
Michiel TubeeckxLaboratory of Physiopharmacology, GENCOR Department, University of Antwerp, Wilrijk, Belgium.
Jens Van FraeyenhoveLaboratory of Physiopharmacology, GENCOR Department, University of Antwerp, Wilrijk, Belgium.
Tine BruynsLaboratory of Physiopharmacology, GENCOR Department, University of Antwerp, Wilrijk, Belgium.
Vincent F M SegersLaboratory of Physiopharmacology, GENCOR Department, University of Antwerp, Wilrijk, Belgium.
Emeline M Van CraenenbroeckResearch Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Wilrijk, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: MiR-181c-5p overexpression associates with heart failure (HF) and cardiac damage, but the underlying pathophysiology remains unclear. This study investigated the effect of miR-181c-5p inhibition on cardiac function and fibrosis in a rodent model of diastolic dysfunction, and evaluated additional effects on kidney as relevant comorbid organ. Methods and results: Diastolic dysfunction was induced in male C57/BL6J mice ( Conclusion: This study demonstrates cardiac anti-fibrotic effects of miR-181c-5p inhibition in a rodent HF model through targeting of

Indexed as

diastolic dysfunctionfibrosisheart failuremiR-181c-5prenal dysfunctionthrombotic microangiopathy

Identifiers

PMID38725830
PMCPMC11079209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.